Mersana Therapeutics, Inc. (NASDAQ:MRSN) was founded in February 2002, formerly known as Nanopharma Corp., and was renamed Mersana Therapeutics, Inc. in November 2005. It is headquartered in Cambridge, Massachusetts, with 83 full-time employees. It is a clinician A biopharmaceutical company at the stage, focusing on the development of antibody drug conjugations (Antibody Drug Conjugates, ADCs) for cancer patients with significant unmet needs.
Mersana Therapeutics (MRSN):
Mersana Therapeutics is a clinical-stage antibody drug conjugate company, using 20 years of industry learning to develop proprietary technology, enabling the company to develop antibody drugs with improved efficacy, safety and tolerability compared with existing ADC treatment methods Conjugate. Mersana Therapeutics’ proprietary technology combined with its deep understanding of goals and patient selection enables Mersana Therapeutics to create precisely targeted treatments that will fundamentally improve patients’ lives.
Taking advantage of technology, Mersana Therapeutics is developing an industry-leading line of pioneering drug products. The company is advancing its proprietary product line through early clinical development and using partnerships with leading companies in the field to accelerate the development of important drugs created on the company’s platform. Mersana Therapeutics’ leading technology platform, Dolaflexin, was included in the company’s first two clinical programs.
Mersana Therapeutics (MRSN) product:
Mersana Therapeutics (MRSN) investment:
Mersana Therapeutics, Inc. (NASDAQ: MRSN) listed on Nasdaq on 6/28/2017 IPO, with an issue price of US$15, 5 million shares issued, and US$75 million raised, stock code: MRSN.